Atria Investments Inc Has $274,000 Holdings in Centessa Pharmaceuticals plc (NASDAQ:CNTA)

Atria Investments Inc raised its position in Centessa Pharmaceuticals plc (NASDAQ:CNTA) by 7.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 17,134 shares of the company’s stock after purchasing an additional 1,116 shares during the quarter. Atria Investments Inc’s holdings in Centessa Pharmaceuticals were worth $274,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Centessa Pharmaceuticals by 47.7% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company’s stock worth $40,000 after buying an additional 826 shares in the last quarter. GAMMA Investing LLC grew its stake in shares of Centessa Pharmaceuticals by 103.1% during the 3rd quarter. GAMMA Investing LLC now owns 2,972 shares of the company’s stock worth $48,000 after acquiring an additional 1,509 shares in the last quarter. Quarry LP increased its stake in Centessa Pharmaceuticals by 47.8% in the 2nd quarter. Quarry LP now owns 9,608 shares of the company’s stock valued at $87,000 after buying an additional 3,108 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in shares of Centessa Pharmaceuticals by 99.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,593 shares of the company’s stock worth $217,000 after buying an additional 6,785 shares during the last quarter. Finally, Sandia Investment Management LP bought a new position in shares of Centessa Pharmaceuticals in the 2nd quarter valued at about $90,000. 82.01% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Centessa Pharmaceuticals news, insider Gregory M. Weinhoff sold 25,000 shares of the firm’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $15.00, for a total value of $375,000.00. Following the sale, the insider now owns 223,369 shares of the company’s stock, valued at approximately $3,350,535. This trade represents a 10.07 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Saurabh Saha sold 1,671 shares of the business’s stock in a transaction dated Friday, November 22nd. The stock was sold at an average price of $18.24, for a total value of $30,479.04. Following the transaction, the chief executive officer now directly owns 575,661 shares of the company’s stock, valued at approximately $10,500,056.64. The trade was a 0.29 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 364,829 shares of company stock worth $5,966,472 in the last 90 days. Company insiders own 11.59% of the company’s stock.

Analyst Ratings Changes

CNTA has been the subject of several recent research reports. Oppenheimer reissued an “outperform” rating and set a $14.00 price target on shares of Centessa Pharmaceuticals in a research report on Wednesday, August 14th. Morgan Stanley upgraded shares of Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $11.00 to $26.00 in a report on Thursday, September 19th. Jefferies Financial Group increased their price target on shares of Centessa Pharmaceuticals from $13.00 to $19.00 and gave the company a “buy” rating in a research note on Wednesday, September 11th. Guggenheim boosted their price objective on shares of Centessa Pharmaceuticals from $24.00 to $28.00 and gave the stock a “buy” rating in a research note on Friday, November 15th. Finally, BMO Capital Markets raised their target price on shares of Centessa Pharmaceuticals from $20.00 to $35.00 and gave the company an “outperform” rating in a research note on Monday, September 16th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $25.83.

Centessa Pharmaceuticals Stock Down 6.3 %

Centessa Pharmaceuticals stock opened at $17.04 on Friday. The company’s 50-day moving average price is $16.09 and its two-hundred day moving average price is $12.38. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15. The stock has a market cap of $1.93 billion, a P/E ratio of -11.14 and a beta of 1.47. Centessa Pharmaceuticals plc has a twelve month low of $5.58 and a twelve month high of $18.74.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its earnings results on Tuesday, November 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.05. As a group, analysts expect that Centessa Pharmaceuticals plc will post -1.62 EPS for the current year.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.